Abstract
AIDS:
Updates are provided for new anti-HIV drugs currently in development. ABT-378, Tipranavir, and DMP-450 are among the new protease inhibitors discussed. Drugs from other classes that are discussed include emivirine (Coactinon, formerly MKC-442), FTC (emtricitabine, Coviracil), adefovir (Preveon), and pentafuside (T-20). A small study has found that women using Ritonavir (Norvir) may be at a greater risk for anemia (a decrease in red blood cells), caused by excessive menstrual bleeding or hypermenorrhea. New formulations of Ritonavir and ddI (Didanosine, Videx) are described.
MeSH terms
-
Adverse Drug Reaction Reporting Systems
-
Anti-HIV Agents / therapeutic use*
-
Capsules
-
Carbamates
-
Chemistry, Pharmaceutical
-
Didanosine / administration & dosage
-
Drug Synergism
-
Drug Therapy, Combination
-
Drugs, Investigational
-
Female
-
Furans
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / administration & dosage*
-
HIV Protease Inhibitors / adverse effects
-
Humans
-
Lopinavir
-
Menorrhagia / etiology*
-
Pyrimidinones / administration & dosage*
-
Reverse Transcriptase Inhibitors / administration & dosage
-
Ritonavir / administration & dosage*
-
Ritonavir / adverse effects
-
Sulfonamides / administration & dosage
Substances
-
Anti-HIV Agents
-
Capsules
-
Carbamates
-
Drugs, Investigational
-
Furans
-
HIV Protease Inhibitors
-
Pyrimidinones
-
Reverse Transcriptase Inhibitors
-
Sulfonamides
-
Lopinavir
-
amprenavir
-
Didanosine
-
Ritonavir